Status:
UNKNOWN
Determining the Safety of L-serine in ALS
Lead Sponsor:
Phoenix Neurological Associates, LTD
Collaborating Sponsors:
Institute for Ethnomedicine
Conditions:
Amyotrophic Lateral Sclerosis (ALS)
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine the safety of L-Serine in subjects with Amyotrophic Lateral Sclerosis (ALS) at varied doses.
Detailed Description
Previous studies into the Guamian ALS-Parkinson's Dementia complex has identified β-methylamino-L-alanine (BMAA), as a potential neurotoxin responsible for this disease. BMAA is a non-essential amino ...
Eligibility Criteria
Inclusion
- Age 18-85
- Male or Female
- Clinically diagnosed with probable or definite ALS based on El Escorial criteria
- ALSFRS-R \> 25
- Able to provide informed consent to and comply with all medical procedures
Exclusion
- Outside age range of 18-85
- Subjects with forced vital capacity (FVC) below 60%
- Evidence of any motor neuron disease for over 3 years
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01835782
Start Date
January 1 2013
Last Update
July 30 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix Neurological Associates
Phoenix, Arizona, United States, 85018
2
Forbes Norris MDA/ALS Research Center
San Francisco, California, United States, 94115